Evidence map›Paper›PMID 39355041›Full record

ArticleFrontiers in nuclear medicine2023

Utilizing MRI, [

Milou Boswinkel, René Raavé, Andor Veltien, Tom Wj Scheenen, Nina Fransén Petterson, René In 't Zandt, Lars E Olsson, Karin von Wachenfeldt, Sandra Heskamp, Irma Mahmutovic Persson

Abstract read
In one paragraph

Article in Frontiers in nuclear medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Imaging technologies in experimental pulmonary fibrosis research: essential tool for enhanced translational relevance.European respiratory review : an official journal of the European Respiratory Society · 2025
    Review
  2. Review
  3. Insights into interstitial lung disease pathogenesis.Breathe (Sheffield, England) · 2025
    Review
  4. Collagen Hybridizing Peptide-Based Radiotracers for Molecular Imaging of Collagen Turnover in Pulmonary Fibrosis.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025
    Article
  5. Frontiers in medicine · 2025
    Article
  6. Review
  7. Frontiers in medicine · 2024
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Milou BoswinkelDepartment of Medical Imaging, Radboud University Medical Centre, Nijmegen, Netherlands.
René RaavéDepartment of Medical Imaging, Radboud University Medical Centre, Nijmegen, Netherlands.
Andor VeltienDepartment of Medical Imaging, Radboud University Medical Centre, Nijmegen, Netherlands.
Tom Wj ScheenenDepartment of Medical Imaging, Radboud University Medical Centre, Nijmegen, Netherlands.
Nina Fransén PettersonTruly Labs, Medicon Village, Lund, Sweden.
René In 't ZandtLund University BioImaging Centre, Faculty of Medicine, Lund University, Lund, Sweden.
Lars E OlssonDepartment of Translational Medicine, Medical Radiation Physics, Lund University, Malmö, Sweden.
Karin von WachenfeldtTruly Labs, Medicon Village, Lund, Sweden.
Sandra HeskampDepartment of Medical Imaging, Radboud University Medical Centre, Nijmegen, Netherlands.
Irma Mahmutovic PerssonLund University BioImaging Centre, Faculty of Medicine, Lund University, Lund, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Accurate imaging biomarkers that indicate disease progression at an early stage are highly important to enable timely mitigation of symptoms in progressive lung disease. In this context, reproducible experimental models and readouts are key. Here, we aim to show reproducibility of a lung injury rat model by inducing disease and assessing disease progression by multi-modal non-invasive imaging techniques at two different research sites. Furthermore, we evaluated the potential of fibroblast activating protein (FAP) as an imaging biomarker in the early stage of lung fibrosis. Methods: An initial lung injury rat model was set up at one research site (Lund University, Lund, Sweden) and repeated at a second site (Radboudumc, Nijmegen, The Netherlands). To induce lung injury, Sprague-Dawley rats received intratracheal instillation of bleomycin as one single dose (1,000 iU in 200 µL) or saline as control. Thereafter, longitudinal images were acquired to track inflammation in the lungs, at 1 and 2 weeks after the bleomycin challenge by magnetic resonance imaging (MRI) and [ Results: Bleomycin-challenged rats showed body weight loss and increased numbers of immune cells and protein concentrations after BAL compared with control animals. The initiation and progression of the disease were reproduced at both research sites. Lung lesions in bleomycin-exposed rats were visualized by MRI and confirmed by histology. [ Conclusion: Here, we demonstrate a reproducible lung injury model and monitored disease progression using conventional imaging biomarkers MRI and [

Indexed as

animal modelsbleomycinfibroblast activating protein (FAP)imaginglung fibrosismagnetic resonance imaging (MRI)positron emission tomography (PET)reproducibility experiments

Identifiers

PMID39355041
PMCPMC11440995

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.